StemCell Therapy

(Thomas Peter/Reuters)

A special Morning Jolt today, as I try to run through a long but by no means complete list of good news from the past year that was astoundingly under-reported and discussed, particularly when compared to presidential tweets, discussions of which pop culture offerings werent woke enough, glowing profiles of the eighth or ninth-most popular Democratic presidential candidate, and so on . . .

Weve Made Some Breathtaking Advances

You will be stunned when you realize how many dramatic breakthroughs have been made against some of the most common and deadly diseases and ailments out there.

One: A new blood test could detect breast cancer five years before other clinical signs manifest. This could be available to patients in four to five years. Separately, a new treatment for early-stage breast cancer could wipe out a growth in just one treatment.

Two: Anewthree-drug combination therapy could provide significant help to up to 90 percent of those suffering from cystic fibrosis.

Three: We could soon see a pill that can prevent heart attacks in high-risk patients: Drugmaker Amarin shocked the world last year when along-running clinical trial showed that itsmedicine derivedfrompurified fish oil, Vascepa, substantially reduced the risk of cardiovascular events like heart attacks in high-risk patients . . . In November,a panel of experts convened by the Food and Drug Administration reviewed Amarinsdata. They voted16 to 0that Vascepa was safe and cuts cardiovascular events.

Four: Israeli researchers think theyve discovered that a molecule designed to help stroke victims may be a new way to wipe out pancreatic cancer, which is one of the toughest cancers to treat.

Five: The Mayo Clinic injected stem cells derived from fat cells into a paralyzed patients spine and the patient is now walking again. This treatment may not work as well for every patient, but it provides new hope for everyone facing paralysis.

You can get stem cells from fat cells? Good heavens, I think Ive found my calling.

Six: A new vaccine could eliminate allergies to cats.

Seven: Earlier this year, UC San Francisco researchers managed to transform human stem cells into mature insulin-producing cells, a major breakthrough in the effort to develop a cure for type 1 diabetes.

Eight: In July, researchers successfully eliminated HIV from the DNA ofinfected mice for the first time,bringing themone step closer to curing the virus in humans.

Nine: Two new treatments for the deadly Ebola virus saved roughly 90 percent of the patients who were newly infected.

Ten: Gene therapy developed atSt. JudeChildrens Research Hospital has cured infants born with X-linked severe combined immunodeficiency, more commonly known as bubble boy disease. The children are producing functional immune cells, including T cells, B cells and natural killer (NK) cells, for the first time.

Keep headlines like the ones above in mind the next time you hear some politician denouncing those greedy pharmaceutical companies.

Turning our attention to the American economy, youve heard about the low unemployment rate. What you may not have heard is that the workforce participation rate for those between 25 and 54 years old is up to 80.1 percent the highest since early 2007.

If thats eleven, then twelve would be the U.S. Census Bureaus latest report on income and poverty, which came out in October. That report found real median family income up 1.2 percent from 2017 to 2018, real median earnings up 3.4 percent, the number of full-time, year-round workers increased by 2.3 million, and the poverty rate declined from 12.3 percent to 11.8 percent, with 1.4 million people leaving poverty.

Thirteen: Despite predictions that Amazon was going to put bookstores out of business, the number of independent bookstores keeps rising each year the most recent figures are 1,887 independent bookselling companies running 2,524 stores.

Fourteen: The cost of lithium-ion batteries is down about 87 percent over the past decade which makes electric vehicles a more cost-effective option for transporting goods and people.

Fifteen: Theres a lot of ugly trade wars and tariffs going on, but there is progress on some fronts. Japan just approved a deal that will lower or remove tariffs on $7.2 billion in U.S. farm goods, including a gradual reduction of its 38.5 percent duty on American beef to 9 percent. Other U.S. products including pork, wine and cheese will also get greater market access, putting the United States on a level playing field with TPP members such as Australia and Canada. The European Parliament voted last month to approve a plan that grants the U.S. a country-specific share of the European Unions duty-free, high-quality beef quota.

Sixteen: In September, for the first time in 70 years, the United States exported more crudeoil and petroleum products than it imported per day. Back in 2006, we were importing 13 million barrels a day. Around that time, America set out to reduce its dependence on foreign oil. Thanks to fracking and innovation, we did it.

Turning our attention to the environment, bald eagles, once on the endangered species list, are now so plentiful that San Bernardino National Forest officials are ending their annual count.

Thats seventeen. Number eighteen would arrive from over in the United Kingdom, a new study of endangered carnivorous mammals finds two of the three rarer carnivores (pine marten and polecat) have staged remarkable recoveries, while the third (wildcat) continues to be threatened by hybridisation. Meanwhile, akin to pine martens and polecats, the formerly rare and restricted otter has recovered much of its former range and is increasing in density.

Nineteen: The world is literally a greener place than it was 20 years ago, and data from NASA satellites has revealed a counterintuitive source for much of this new foliage: China and India. A new study shows that the two emerging countries with the worlds biggest populations are leading the increase in greening on land. The effect stems mainly from ambitious tree planting programs in China and intensive agriculture in both countries.

Twenty: NASA also found that abnormal weather patterns in the upper atmosphere over Antarctica dramatically limited ozone depletion in September and October, resulting in the smallest ozone hole observed since 1982.

Twenty-one: A study unveiled in November estimates that humpbacks in the western South Atlantic region now number 24,900 nearly 93 percent of their population size before they were hunted to the brink of extinction. Good news, crew of the Enterprise, you may not need to use a stolen Klingon ship to find two humpbacks to save the future.

Twenty-two: The National Oceanic and Atmospheric Administration spotted and recorded video of a kraken okay, a giant squid that was at least 10 feet long only about 100 miles southeast of New Orleans, shortly before their vessel was struck by lightning. Okay, technically this could be bad news.

Turning our attention overseas, you heard about the raid against al-Baghdadi and the collapse of the Islamic State. You probably didnt hear that the number of ISIS fighters in Afghanistan is now reduced to around 300 fighters in Afghanistan, from an estimated 3,000 earlier this year.

Thats twenty-three; twenty-four would be the impact of terrorism. We wont know 2019s numbers until the year ends, but deaths from terrorism fell for the fourth consecutive year in 2018, after peaking in 2014. The number of deaths has now decreased by 52 percent since 2014, falling from 33,555 to 15,952, says the 2019Global Terrorism Index.

Twenty-five: The number of malaria infections recorded globally has fallen for the first time in several years. In 2018, Cambodia reported zero malaria-related deaths for the first time in the countrys history. India also reported a huge reduction in infections, with 2.6 million fewer cases in 2018 than in 2017.

Twenty-six: Tensions between India and Pakistan got worse overall this year over Kashmir, but India and Pakistanmanaged to cooperate on breaking ground on a new peace corridor that will allow more than 5,000 Sikh pilgrims to travel back and forth across the normally impassable border visa-free for the first time in 72 years.

Twenty-seven: Israeli scientists have genetically engineered an E. Coli bacteria that eat carbon dioxide.

Twenty-eight through thirty-one come from the realm of remarkable discoveries about our past. Archeologists made amazing discoveries in the past year. A 1,300-year-old rook found in the Jordanian desert may be the worlds oldest chess piece. They discovered a new humanoid Nazca line in Peru. Sometime fourth century B.C. and sixth century A.D., in what is today Iran, some civilization built a big beautiful wall running about 71 miles; it appears Mexico didnt pay for that one, either. And in Jerusalem, archeologists found that a grand street running from the Siloam Pool to the Temple Mount was built by some guy named . . . er, Pontius Pilate.

You hear about this stuff a lot less because articles and television segments about these developments dont make you more likely to respond in the comments section, more likely to share on social media, more likely to call into a talk radio program, or more likely to vote for a particular candidate. It doesnt make you believe that the world is full of people who are being unfair to you, that youre a victim, or that other people are responsible for your problems.

ADDENDUM: Whatever your day holds, it probably doesnt include chaperoning an elementary school field trip with fourth graders that includes long bus rides to and from our educational destination. Heres hoping not too many kids barf today.

Read the original post:
The World Is Getting Better. Its Just That No One Tells You About It. - National Review

Jesse and Diane

POWAY, Calif. (PRWEB) December 03, 2019

Bold Brahim aka Jesse, a Spanish Arabian, was 11 years old when he suddenly went non-weightbearing lame on his right front leg. After several weeks of medical management, his condition worsened so his owner, Diane, sought a bone scan and MRI with Dr. Mark Martinelli of California Equine Orthopedics. Results revealed Jesse had a severe injury to his deep digital flexor tendon in his right front hoof capsule. Due to the severity of the injury, Dr. Martinelli recommended treatment with VetStem Cell Therapy and also referred Jesse to Dr. Sylvia Ouellette who specializes in equine lameness diagnosis and treatment.

Diane started an extensive rehabilitation plan laid out by Dr. Ouellette. The initial projection was that Jesses tendon would require a minimum of 15-18 months of diligent rehabilitation if it stood any chance of healing. At the same time, both veterinarians continued to recommend Jesse receive VetStem Cell Therapy to improve his chances of success. After researching the treatment and having a setback in the rehab, Diane agreed to move forward with stem cell therapy.

Dr. Ouellette collected fat from Jesses tailhead in a minimally invasive surgical procedure. The fat was packaged and shipped overnight to the VetStem laboratory in Poway, California. Once received, VetStem laboratory technicians processed the fat to extract Jesses stem and regenerative cells and created an injectable stem cell dose. Jesses stem cell injection was prepared for Dr. Martinelli who received and injected the cells within 48 hours of the initial collection. Jesse received one injection into his injured tendon.

Jesse and Dianes journey was not over yet, however. Jesse continued a rigorous rehabilitation schedule and experienced a few setbacks after which his improving lameness regressed. It was two years after his initial injury when Diane finally received the good news that Jesse was sound.

In a recent update from Diane, she reported that Jesse is now 24 years old and his tendon has remained sound. She stated, Though he has other age-related health issues, the deep flexor tendon has stayed strong and has served him well all of these years.

Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a clinical case series using VetStem Regenerative Cell Therapy in horses with tendon and ligament and joint injuries, it was found that VetStem Regenerative Cell Therapy helped these horses to return to full work or to the activity level that the owner desired.

About Mark Martinelli, DVM, PhD, DACVS, DACVSMRDr. Martinelli received his DVM from Michigan State University. He completed a surgical residency at the University of Illinois and then moved to Scotland where he lectured in equine surgery while completing a PhD in joint disease. He received his Diplomate status with the American College of Veterinary Surgeons in 1998. Dr. Martinelli owns California Equine Orthopedics where he specializes in the diagnosis and medical or surgical treatment of sports medicine issues of the equine athlete.

About Sylvia Ouellette, DVM, DABVPDr. Ouellette received her DVM from the University of California at Davis in 1995. She currently practices in Oregon at Oakhurst Equine Veterinary Services. In 2005 Dr. Ouellette became board certified as an equine specialist with the American Board of Veterinary Practitioners. She specializes in lameness in the sport horse.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Continued here:
VetStem Biopharma Shares the Success Story of Jesse Who was Treated with VetStem Cell Therapy - PR Web

ANI | Updated: Dec 02, 2019 12:07 IST

Taipei [Taiwan] Dec 2 (ANI/Digpu): The immunotherapy used by Guang-Li Biomedicine and Taipei Medical University Hospital brings new hope to the terminal patients of solid cancer.The international journals Cell and Science have reported that immune cell therapy is a new generation of anti-cancer weapons. The immuno-cell therapy developed by Guang-Li Biomedicine and Taipei Medical University Hospital uses the human body's immune system to attack tumour cells. This major breakthrough in cancer treatment has prolonged the life of many cancer patients who were previously incurable and even cured them.With cell therapy officially allowed in Taiwan, Guang-Li Biomedicine and Taipei Medical University Hospital are leading Taiwan's many medical institutions and research units in legalizing cancer treatment programs. The Guang-Li Experimental Center took advantage of stem cell storage patents and immune cell preparation technology and successfully submitted application and received approval of CIK immune cell therapy for 12 solid cancers, bringing top medical technology to patients."The clinical trial of the hospital and Guang-Li Biomedicine has been approved. Highly active Cytokine-induced killer cells (CIK) can be used on first-to third-stage cancer patients that do not respond to treatment effects, as well as patients in the fourth phase of solid cancer, which is currently a more effective way to prolong life and cure cancer than other therapies", said Lee, Kuan-Der, deputy dean of Taipei Medical University Hospital.The indication of approved projects includes colorectal cancer, breast cancer, lung cancer, cervical cancer, ovarian cancer, kidney cancer, liver cancer, pancreatic cancer, nasopharyngeal cancer, stomach cancer, oesophageal cancer, and cholangiocarcinoma.In the past, cancer treatment, regardless of surgery, chemotherapy, radiation therapy, is to remove tumor cells from the outside, but Taiwanese law already allows the use of autologous cells for autoimmune cell therapy, and there are many successful cases for patients with stable cancer. In addition, Taiwan has also opened up autologous chondrocyte transplantation, autologous fat stem cell transplantation, skin repair, wound healing, and articular cartilage regeneration.This story is provided by Digpu. ANI will not be responsible in any way for the content of this article. (ANI/Digpu)

See more here:
Cell therapy options at Guang-Li Biomedicine and Taipei Medical University Hospital bring hope to cancer patients - ANI News

Agriculture

Published on December 2nd, 2019 | by Chanan Bos

December 2nd, 2019 by Chanan Bos

Image: Screenshot of Multus Media website

As everyone knows, while real meat is extremely tasty and hard to part with for a lot of people, it is also extremely wasteful, requires a lot of water, plants, and the energy to grow an animal. At the same time, this produces a lot of CO2 and methane thanks to processes like respiration and digestion. Also, killing animals for meat presents some ethical dilemmas.

In any case, this article is about Multus Media, a UK-based startup that doesnt make lab-grown meat. Multus Media plans to supply a lot of companies that will grow the meat. Acquiring and programming the stem cells needed for cultivated meat is only one part of the problem, while the other part is finding ways to feed those cells without growing a whole digestive system or whole animal. What we are talking about here is a very important component called the growth medium.

Right now, the cost of serum-free growth medium is approximately $100 per liter and represents about 80% of the total cost of production of clean cultivated meat. In order to make clean meat a competitive alternative to regular meat, the price of the growth medium needs to fall down all the way to just $1 per liter. Multus Media has found a way to reduce the current price by about 80%, but is unwilling to give an exact number because this is based off of preliminary data and it is still finalizing the results, however, if one thing is clear then its that significant progress has been made here.

The way Multus Media achieved this milestone was by genetically altering yeast to produce the complex proteins required for the growth medium which are then extracted using the fermentation process, so from the outside a factory making growth medium will look a lot like a factory producing beer. If any of this sounds familiar to you, that is probably because the Impossible Burger is made in a very similar way. The secret sauce of the Impossible Burger is a plant-based heme that is present in soy but only in minute quantities, so the company modified yeast to produce much more of this heme and then extracts it using the fermentation process. In some ways this has been done for years to make the proteins found in milk and eggs, but in the case of fake meat they make plant-based heme, and in the case of lab-grown meat they make the proteins needed to grow muscle tissue cells without growing a whole animal.

Currently, the company is attempting to lower the costs further, but by 2021 it hopes to start a commercially viable system for the production of a limited number of growth factors that can then be scaled up. Afterward, the company will start developing growth factors for non-mammalian cells like seafood and poultry such as chicken.

The possibilities of this technology are endless, and just to ignite your imagination let me give you an example. In Japan there is a fish delicacy called Fugu made from an extremely poisonous blowfish, and training a chef to prepare the dish safely takes many years of practice because the slightest mistake will kill the customer. Now imagine growing the delicacy without the actual fish, without any of the poison. Or if we have the DNA of extinct species like the Dodo or the Heath Hen (which Thanksgiving started with rather than Turkeys) we could literally start rediscovering new kinds of foods people havent eaten in centuries. As a matter of fact, bringing an extinct species back to life is more difficult than just growing its meat. Another example is that cultivated meat can be designed to conform to specific criteria, such as what percentage of fat it should have or the percentage of different types of saturated amino-acids it should have, and so on.

This is all part of synthetic biology, which is a fascinating subject we have written on before and will dive deeper into in future videos and articles.Follow CleanTechnica on Google News.It will make you happy & help you live in peace for the rest of your life.

Tags: lab-grown meat, Multus Media

Chanan Bos Chanan grew up in a multicultural, multi-lingual environment that often gives him a unique perspective on a variety of topics. He is always in thought about big picture topics like AI, quantum physics, philosophy, Universal Basic Income, climate change, sci-fi concepts like the singularity, misinformation, and the list goes on. Currently, he is studying creative media & technology but already has diplomas in environmental sciences as well as business & management. His goal is to discourage linear thinking, bias, and confirmation bias whilst encouraging out-of-the-box thinking and helping people understand exponential progress. Chanan is very worried about his future and the future of humanity. That is why he has a tremendous admiration for Elon Musk and his companies, foremost because of their missions, philosophy, and intent to help humanity and its future. He sees Tesla as one of the few companies that can help us save ourselves from climate change.

Visit link:
Lab-Grown Meat In Supermarkets Is Closer Than You Think, Thanks To Growth Medium Breakthrough - CleanTechnica

These days, one quick look at the internet would show you numerous types of diet strategies that all promise weight loss with some additional health loss. And while most of them do work, not a single one of them is gaining traction in the actual health expert world as much as intermittent fasting, which is now being lauded as a really effective way to control the development of chronic illnesses while also helping you lose the pounds you want to shed off.

In fact, research is also showing that when it comes to reducing body mass index (BMI) and improving glycemic control, an intermittent fasting diet can be really beneficial.

Intermittent Fasting

As a diet, intermittent fasting involves cutting calories either in whole or in part while also compressing your eating window time. This can be done every other day, a couple days a week, or even daily. This is because when you go throughout a normal day by eating all your meals in time, your body gets used to using sugar as fuel for energy. This means that the enzymes that both utilize and burn fat thats stored in your body gets regulated. When you follow this diet, however, your body will be pushed to use fat as energy, burning it in the process and helping you lose weight.

As per research, there are also other ways that intermittent fasting can help take your health to the next level. This includes lowering your triglyceride levels, improving the management of your blood sugar, promoting insulin and leptin sensitivity, increasing the production of the human growth hormone, suppressing inflammation and helping reduce the damage done by oxidation, and lowering your overall blood pressure. Additionally, it can also help you reduce the risk of heart disease, improve your immune function, prevent (or reverse) type 2 diabetes, shift stem cells from a dormant state to self-renewal, boost mitochondrial energy efficiency, reproduce cardiovascular benefits you usually obtain from physical exercise, increase longevity, improve cognitive function, protect against neurological diseases, regenerate the pancreas and improve its function, and eliminate sugar cravings since your body adapts to burning fat.

Doctor Carlos Pineiro weighs a woman at the town's health center in Naron, on September 13, 2018. Intermittent fasting can be adopted in different regimens and contribute to weight loss. Miguel Riopa/AFP/Getty Images

Go here to see the original:
Intermittent Fasting: Reasons Why You Should Embrace This Eating Plan - Medical Daily

PALO ALTO, Calif.--(BUSINESS WIRE)-- Jasper Therapeutics, Inc., a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies, today announced the launch of the company with a $35 million total Series A financing. Abingworth LLP and Qiming Venture Partners USA served as lead investors, with further investment from Surveyor Capital (a Citadel company) and participation from Alexandria Venture Investments, LLC. The proceeds will be used to advance the clinical development of the companys lead product candidate, JSP191, which is designed to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplant.

Jaspers development of JSP191 is also supported by a collaboration with the California Institute for Regenerative Medicine (CIRM), which has been funding the program and is committed to providing a total of $23 million in grant support. As part of the Series A financing, Amgen, which discovered JSP191 (formerly AMG191), has licensed worldwide rights to Jasper that also include translational science and materials from Stanford University.

Jasper was co-founded by Judith Shizuru, M.D., Ph.D., a hematopoietic stem cell transplant expert at Stanford University, and Susan Prohaska, Ph.D., a Stanford University-trained immunologist, stem cell biologist and early-stage drug development professional. Dr Shizurus CIRM-funded lab advanced the understanding of the ability of anti-CD117 to impact hematopoietic stem cells and, together with the Lucile Packard Childrens Hospital Stanford and University of California, San Francisco (UCSF) pediatric transplant teams, was the first to study an anti-CD117 antibody in the clinic as a conditioning agent. That humanized antibody, now called JSP191, was first studied for conditioning for transplant in immune-deficient patients in collaboration with Amgen, UCSF and CIRM.

Stem cell transplantation is a potential curative therapy for people with hematologic cancers, autoimmune diseases, and debilitating genetic diseases. However, the pre-transplant conditioning required to prepare patients for transplant involves highly toxic chemotherapy, which can be life-threatening and limits the number of people who are able to benefit, said Dr. Shizuru, co-founder and member of the Board of Directors of Jasper Therapeutics. JSP191 is the only anti-CD117 antibody to demonstrate safety and efficacy in severely ill patients receiving stem cell transplant in the clinic. We plan to expand clinical development to patients receiving transplants for acute myeloid leukemia/ myelodysplastic syndrome or autoimmune diseases and to patients receiving stem cell-directed gene therapies.

Dr. Shizuru added, With an experienced executive team of biotech veterans and a strong syndicate of healthcare-focused investors, Jasper Therapeutics is well positioned to achieve our vision of building a leading biotech company starting with JSP191 and expanding to other novel therapies for immune modulation, graft engineering and cell and gene therapies.

JSP191 is currently being evaluated in an ongoing Phase 1 clinical trial as a conditioning agent to enable stem cell transplantation in patients with severe combined immunodeficiency (SCID) who received a prior stem cell transplant that failed. This severe genetic immune disorder leaves patients without a functioning immune system. Interim results of the study will be presented in an oral presentation (abstract #800) on Monday, December 9, at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Fla. Clinical studies to evaluate the safety and efficacy of JSP191 as a conditioning agent in patients undergoing hematopoietic cell therapy for hematologic cancers are planned for 2020.

Founding Management Team

Dr. Shizuru and Mr. Lis are joined on the Jasper Therapeutics Board of Directors by Kurt von Emster, Managing Partner of Abingworth LLP, and Anna French, Ph.D., Principal at Qiming Venture Partners USA. Dr. Prohaska is a Board observer.

With our investment in this program, were able to realize our mission of fast-tracking stem cell treatments by helping academic researchers rapidly advance the most promising discoveries in the lab into the clinics and to drug development with commercialization partners, said Maria T. Millan, M.D., President and CEO of CIRM. Jaspers two co-founders took a novel antibody with unique properties and moved it from the bench to the bedside relatively quickly, and were thrilled to partner with this talented team to potentially impact a broad group of people who could benefit from stem cell therapy.

About Stem Cell Transplantation

Blood-forming, or hematopoietic, stem cells are cells that reside in the bone marrow and are responsible for the generation and maintenance of all blood and immune cells. These stem cells can harbor inherited or acquired abnormalities that lead to a variety of disease states, including immune deficiencies, blood disorders or hematologic cancers. Successful transplantation of hematopoietic stem cells is the only cure for most of these life-threatening conditions. Replacement of the defective or malignant hematopoietic stem cells in the patients bone marrow is currently achieved by subjecting patients to toxic doses of radiation and/or chemotherapy that cause DNA damage and lead to short- and long-term toxicities, including immune suppression and prolonged hospitalization. As a result, many patients who could benefit from a stem cell transplant are not eligible. New approaches that are effective but have minimal to no toxicity are urgently needed so more patients who could benefit from a curative stem cell transplant could receive the procedure.

Safer and more effective hematopoietic cell transplantation regimens could overcome these limitations and enable the broader application of hematopoietic cell transplants in the cure of many disorders. These disorders include hematologic cancers (e.g., myelodysplastic syndrome [MDS] and acute myeloid leukemia [AML]), autoimmune diseases (e.g., lupus, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes), and genetic diseases that could be cured with genetically-corrected autologous stem cells (e.g., severe combined immunodeficiency syndrome [SCID], sickle cell disease, beta thalassemia, Fanconi anemia and other monogenic diseases).

About JSP191

JSP191 (formerly AMG191) is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, causing the stem cells to undergo cell death and creating an empty space in the bone marrow for donor or gene-corrected transplanted cells to engraft.

Preclinical studies have shown that JSP191 as a single agent safely depletes normal and diseased hematopoietic stem cells, including in an animal model of MDS. This creates the space needed for transplanted normal donor or gene-corrected hematopoietic stem cells to successfully engraft in the host bone marrow. To date, JSP191 has been evaluated in more than 80 healthy volunteers and patients. It is currently being evaluated as a sole conditioning agent in a Phase 1 dose-escalation trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for SCID, which is curable only by this type of treatment. For more information about the design of the clinical trial, visit http://www.clinicaltrials.gov (NCT02963064). Clinical development of JSP191 will be expanded to also study patients with AML or MDS who are receiving hematopoietic cell transplant.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. Jasper Therapeutics lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant. For more information, please visit us at http://www.jaspertherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005456/en/

Original post:
Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to...

Analysis of the Stem Cell Therapy Market

A recent market study published by Persistence Market Research on the Stem Cell Therapy Market maps the growth trajectory of the Stem Cell Therapy Market over the forecast period 2020. The report tracks the major developments that have made the headlines in the Stem Cell Therapy Market space and touches upon development projects in the pipeline. The report provides a thorough assessment of the micro and macro-economic factors that are likely to influence the growth of the Stem Cell Therapy Market in the upcoming years.

As per the findings of the report, the Stem Cell Therapy Market is slated to grow at a CAGR of ~XX% during the forecast period and attain a market value of ~US$XX by the end of 2029. The report introspects the various factors that are anticipated to have a significant impact on the growth of the Stem Cell Therapy Market over the assessment period 2020.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/3253

Important Queries Addressed in the Report:

The report on the global Stem Cell Therapy Market offers a detailed analysis of the various segments of the market with utmost precision. The growth prospects of each segment is accurately represented in the report along with relevant graphs and figures.

Valuable Insights Included in the Report

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/3253

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/3253

Why Opt for PMR?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

More here:
Stem Cell Therapy Market Segmentation: Based on Product, Application and Region by 2020 - The Market Expedition

The research report Healthcare Nanotechnology Market Global Industry Analysis 2019 2025 offers precise analytical information about the Healthcare Nanotechnology market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Healthcare Nanotechnology Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Healthcare Nanotechnology industry.

This Healthcare Nanotechnology market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Healthcare Nanotechnology market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#RequestSample

Competitive Landscape

Global Healthcare Nanotechnology market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International

Market Segmentation

Healthcare Nanotechnology Market report segmentation on Major Product Type:Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other

Market by Application: Here, various application segments of the global Healthcare Nanotechnology market are taken into account for the research study.

Anticancer, CNS Product, Anti-infective, Other

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#InquiryForBuying

Regional Analysis

The Healthcare Nanotechnology market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Healthcare Nanotechnology Market Report:-

What will the market growth rate, overview, and analysis by type of global Healthcare Nanotechnology Market in 2026?

What are the key factors driving, analysis by applications and countries Global Healthcare Nanotechnology Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Healthcare Nanotechnology Market?

Who are the opportunities, risk and driving forces of the global Healthcare Nanotechnology Market?

Who are the opportunities and threats faced by the vendors in the Global Healthcare Nanotechnology Market?

What are the Global Healthcare Nanotechnology market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Read more:
Global Healthcare Nanotechnology Market 2019 by Company, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

The Nanomedicine research report is a valuable source of data for business strategists. It provides the Nanomedicine overview with growth analysis and historical and futuristic cost revenue demand and supply data. The research analysis provides an elaborative description of the value chain and distributor analysis.

Request Sample Copy of This Report: @https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Free-Sample-Report

The Nanomedicine market study provides comprehensive data that enhance the understanding, scope and application of this report.

The report provides a basic overview of the industry including definitions and classifications. The Nanomedicine analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Prominent players of Nanomedicine market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report studies the Nanomedicine status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyses the top players in global market, and splits the Nanomedicine By product type and applications/end industries.

Read Detailed Index of full Research Study at @ https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/

To comprehend 2018-2026 Nanomedicine dynamics in the world mainly, the worldwide 2018-2026 Nanomedicine is analyzed across major global regions. Nanomedicine Also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, etc

The study objectives of this report are:

To study and forecast the market size of Nanomedicine

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end-use and region.

To analyses and compare the market status and forecast among global major regions.

To analyses the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting market growth.

TOC-

Check here for the discount@https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@99marketresearch.com), who will ensure that you get a report that suits your needs.

See the article here:
Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - Med News Ledger

World Longevity Economy Size Projections, current USD

AI for Longevity has more potential to increase healthy Longevity in the short term than any other sector. The application of AI for Longevity will bring the greatest real-world benefits and will be the main driver of progress in the widespread extension of healthy Longevity. The global spending power of people aged 60 and over is anticipated to reach $15 trillion annually by 2020. The Longevity industry will dwarf all other industries in both size and market capitalization, reshape the globalfinancial system, and disrupt the business modelsof pension funds, insurance companies, investment banks, and entire national economies.

Longevity has become a recurring topic in analytical reports from leading financial institutions such as CitiBank, UBS Group, Julius Baer, and Barclays. At the recent AI for Longevity Summit in London, top executives from Prudential, HSBC, AXA Insurance, NVIDIA, Microsoft, Babylon Health, Insilico Medicine, Longevity.Capital, Longevity Vision Fund, Juvenescence, Deep Knowledge Ventures, and the UK All-Party Parliamentary Group for Longevity came together to discuss the Longevity Industry. International policymakers and senior corporate executives shared learnings from Japan, Israel, Switzerland, the US, and the UK and exchanged ideas on beginning to work together in a new social contract to enhance global prosperity equitably.

The 7th Continent - 1 Billion People in Retirement Globally

Switzerland is one of the most longevity progressive countries in the world with both high investment in biotechnology and the capacity to integrate AI into its economic, financial, and healthcare systems. Switzerland has the potential to be a world leader in both the Global Longevity Industry and the 4th Industrial Revolution. There are currently 100 companies, 80 investors, 50 financial companies, 35 research labs, 20 precision medicine clinics, 15 nonprofits, and 10 governmental organizations in the Swiss Longevity Industry. Switzerland is in an excellent position to retain its leading position by focusing on the optimal assembly of its existing resources to transform the challenge of demographic aging into a national asset.

Switzerland has a large aging population and Swiss investment banks are acutely aware of the oncoming demographic challenge. Switzerland is one of the most efficiently regulated and supervised financial centers in the world and has been leading transformative developments emerging from the digitalization of its banking and financial sector. Longevity-progressive countries typically have large aging populations, and aging populations have two longevity-progressive benefits: voting power and spending power.

Longevity Industry in Switzerland 2019

The digitization of finance, and novel financial systems which treat Longevity as a dividend, will play an integral role in the Longevity economy. According to a recent report by Aging Analytics Agency, Switzerland has the elements necessary to become a leading Longevity financial hub, including factors such as a lean political system that facilitates rapid implementation of integrated government programs, a strong research environment for geroscience, a strong research and business environment for digital health, and most importantly, international financial prowess.

Switzerland has the ability to develop several Longevity specific programs over the next several years. One program is a Longevity progressive pension system and insurance company ecosystem that accounts for both population aging (which threatens to destabilize the current business models of insurance companies and pension funds) and the potential for widespread healthspan extension. Another program is a national strategy for intensively developing Geroscience and FinTech to a state so advanced that it propels Switzerland into a central role in the international Longevity business ecosystem and a global leader in Longevity Finance. Switzerland is leading the digitization of financial markets and establishing itself as a catalyst for financial innovation on a global level. According to Aging Analytics Agency, 10% of all European FinTech enterprises are located in Switzerland.

Switzerland has a strong and productive geroscience community and has gained prominence among investors as a global biotech hub and hotbed of innovation. The Swiss Institute for Bioinformatics has recently identified large numbers of genetic markers directly linked to human life expectancy. Switzerland is also home to the prestigious Vontobel Prize for Aging Research.

The Convergence of 5 Mega Trends

BioValley

Switzerland is situated at one end of the BioValley - one of the leading life science clusters in Europe. This cluster is unique in that it spans across three countries, Switzerland, Germany and France, and includes Basel, a global life science hub. BioValley brings together important ingredients for a successful biotech cluster including a concentration of companies, rich availability of skills, experience within Life Sciences, and a world class research base. The cluster in Switzerland has in excess of 50,000 people working in the life sciences field including 15,000 scientists. There are 600 companies in the cluster developing therapeutic, diagnostic or medical devices to address a wide range of diseases in multiple therapeutic classes. There are 100,000 students enrolled in 10 universities and research institutions including University of Basel, Max Planck Institute, and Freiburg University. The cluster has produced a number of spin-out companies supported by a financial network including both public and private financing initiatives as well as traditional venture capital and private equity. The entire process of drug development is covered in the region, from research through to clinical and drug development, and manufacturing.

Longevity AI Consortium Expands to Switzerland

Longevity AI Consortium King's College London

In November 2019, Europes firstLongevity AI Consortium(LAIC)launched at King's College London. LAIC is currently developing collaborative research projects withDynamics of Healthy Ageing (DynAge)and theDigital Society Initiative (DSI)at the University of Zurich. The research will utilize AI technologies to predict the future cognitive ability of individuals using multimodal neuroimaging and risk factor data. Academics in Zurich will work in collaboration with colleagues at the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. LAIC plans to establish several collaborative projects with the University of Zurich in 2020. The joint R&D between Ageing Research at Kings and University of Zurich forms the first phase of the global Longevity AI Consortium that will eventually be extended to Israel, Singapore, Japan and the US.

The Longevity Industry

AgeTech

FinTech banks are redefining the banking industry by connecting with a new generation of mobile-first consumers. However, FinTech banks are focusing on consumers who are middle-age and younger, not on the 1 billion people in retirement and the $15 trillion dollar market opportunity. As the share of the population over 60 increases, Swiss banks are lagging behind in finding solutions for this age group. Traditional banks, as opposed to challenger banks, are making their first steps in AgeTech, adapting their infrastructure for people over 60.

WealthTech

The WealthTech Industry refers to a new generation of financial technology companies that create digital solutions to transform the investment and asset management industry. New companies have arrived on the scene offering advice based on AI and big data, micro-investment platforms, and trading solutions based on social networks. A growing aging population is one of the main drivers of innovation in WealthTech. Financial services innovators have an opportunity to enhance the financial lives of individuals over 60 by designing new solutions and adapting existing products and services for them. This is an opportunity to implement innovations that address financial health challenges head on.

Financial Wellness

As a core component of its mission to develop Switzerland into a leading international Longevity Financial Industry hub, Longevity Swiss Foundation plans on roadmapping the development of AI Centers for Financial Wellness. Whereas the proposed AI Centers for Longevity would focus on optimizing health, these centers would focus on the application of AI to the creation of methods and technologies to promote wellness in other areas including financial wellness, continuing education, psychological well being, neuroplasticity, and active social involvement. The planned development of AI Centers for Financial Wellness will enable financial stability over extended periods of healthy Longevity for Swiss citizens.

Switzerland could become the center of the Longevity Financial Industry. Given its geographic size and its reliance on international cooperation, its function in the Longevity Industry will be as a small but important node. Due to its status as an international BioTech epicenter and its reputation as one of the most progressive countries in terms of its financial industry, the prospects for Switzerland to lead the world in the development of its Longevity Financial Industry are strong.

Today, change occurs at the intersection of two or more scientific and technological domains. We are at the beginning of a trend where the degree of complexity and the number of convergence points will increase exponentially. The convergence of AI, advanced data science, and Longevity research will accelerate important medical breakthroughs that will benefit all humans. In the next decade, the Longevity Industry will impact many areas of our lives. Longevity policies enacted by governments and changes in the global financial industry will transform society. Achieving small but practical results in Longevity distributed at scale will have enormous and multiplicative effects on society. Extending the functional lifespan of humans by just one year will decrease suffering for tens of millions of people and will improve the quality of life for billions of people.

See the original post here:
AI Will Drive The Multi-Trillion Dollar Longevity Economy - Forbes

In a recent study undertaken by scientists from the National Institutes of Health and National Institute of Aging, researchers found the secret to longevity is linked with meal times.

The researchers separated 292 male mice into two groups and gave them different diets. They also examined how altering the meal times affected the life expectancy of the mice. At the end of the study period, the scientists found the results to be very impressive and concluded that the same might be true for humans. happy man longevity Photo: rottonara - Pixabay

They said the findings provided a beacon of hope for future studies and at the same time, suggested a particular diet to help improve longevity. This study, which was participated in part by scientists from the Pennington Biomedical Research Centre and the University of Wisconsin-Madison, analyzed how longer fasting times could boost health and longevity. Researchers noted that increasing the time between meals improved the overall health of the male mice. They also lived longer compared to the other group who were fed and ate more frequently.

The scientists also report that health and life span greatly improved with increased fasting times, notwithstanding the type of food the mice ate or how many calories the food contained.Dr. Richard J. Hodes, a director at the NIA, said that the study revealed that the group of mice that consumed only one meal daily appears to enjoy a longer lifespan. They also seem to have better outcomes for age-related ailments like liver disease and a number of metabolic disorders.

He also said that the fascinating results using lab mice as the model which revealed the relationship of fasting and feeding time length and total caloric intake deserve a closer examination.

Dr. Rafael de Cabo, the studys lead author and Translational Gerontology Branch chief of the NIA Intramural Research Program, said increasing daily fasting times improved the overall health of male mice. He also said that their survival chances in a number of age-related ailments also increased. These positive results occurred regardless of the caloric intake and the type of diet the mice have.

The lead author hypothesized that the extended fasting period might have enabled the maintenance and repair mechanisms of the mices bodies to kick into place. Such a process would have been absent had the mice ate food continuously.Researchers of the study also revealed the results seem to suggest that those who are able to fast at least once a month may enjoy a longer and healthier life.

View original post here:
You Can Improve Longevity By Having This Diet At Least Once A Month - International Business Times

Courtesy South Shore YMCA Ruth Kundsin, 103, works out with her personal trainer Dick Raymond at the South Shore YMCA in Quincy, Massachusetts.

People lifting weights at a gym in suburban Boston can be forgiven if they have no clue the energetic woman working out next to them is 103 years old.

Ruth Kundsins exercise routine includes cardio and strength training, a lifestyle thats more active now than the decades she spent working as a microbiologist only reluctantly retiring in her 80s.

She still lives on her own, loves parties and works out with a personal trainer every Friday at the South Shore YMCA in Quincy, Massachusetts.

I feel better afterwards and I think its keeping me vertical, Kundsin told TODAY, expressing surprise at all the excitement about her centenarian status.

Its really funny to me. I think Ive gotten more accolades for my age than I have for my science and thats sort of strange because you have nothing to do with your age. I mean, you just age, but the science I really worked hard on.

Dick Raymond, who has been her personal trainer for 10 years, said weights are the most important part of her routine.

We work every part of her body trying to keep her strong, Raymond, 69, noted. The older you get, the more you need exercise because you lose strength as you age. You can prevent that you can get better at any age.

Heres what Kundsin attributes to her longevity:

Kundsin described herself as having a very upbeat, optimistic, happy outlook on life. If something disturbs her, she gets over it, she said.

Its very important to have something to look forward to. If you dont have anything to look forward to, life is bleak and dull. But it seems like I always have something to look forward to and if there isnt anything, I make it, like I throw a party, Kundsin said.

I know that no matter how bad I feel, in a little while, Ill be feeling pretty good. I dont really worry about anything any great length of time.

The daughter of Latvian immigrants, Kundsin received a doctorate of science from Harvard School of Public Health in 1958.

Kundsin felt passionate about her work as a scientist and insisted on working even though it upset her family at a time when women were expected to stay home with their children.

She was the first mother to work in her community, facing intense scrutiny from her neighbors. Even Kundsins husband didnt want her to work, but she got her own way.

Thank goodness. Now I know it was the right thing to do, she said. Its a satisfaction to have a job I loved my work.

Kundsin had 150 papers published in scientific journals and wrote five books. She worked as an associate professor at Harvard Medical School until she was 81.

Scientific work is sedentary, so after spending much of her life bent over a microscope, Kundsin decided she had to make up for it when she retired.

When an acquaintance invited her to come to a gym, she thought it would be fun and has been exercising regularly ever since. She particularly liked swimming, taking part in Senior Games and competing at the national level three times.

She started working out with Raymond at age 93. The personal trainer focuses on having her do exercises that are challenging for her because challenging things are what improve you. Easy things dont improve you, he said.

Besides her weekly workouts, Kundsin cooks for herself and takes care of her house, doing chores and climbing up and down stairs, which Dick approves of, she said.

Kundsin isnt the first centenarian Raymond has worked with. He at one point also trained his father, who recently passed away at 101.

Unlike many centenarians TODAY has profiled, Kundsin smoked cigarettes for many years and didnt quit until her 70s. Still, she hasnt had any major health problems like cancer or heart disease, she said. Its only within the past year that shes started using a cane because of balance issues.

Kundsin doesnt eat beef, but otherwise does nothing special when it comes to her diet.

Influenced by Raymonds advice, she now eats oatmeal topped with lots of fruit for breakfast and has started avoiding sugar after a lifetime of eating desserts.

She drinks a glass of wine every night not because she loves it but because she believes its good for health. Indeed, research of people who lived to 90 and beyond found those who drank moderate amounts of alcohol lived longer than those who abstained.

I should be drinking red wine, but I think its a little strong for me so I drink white wine. I prefer champagne, Kundsin said.

Related Video: 104-Year-Old Runner Shares Her Longevity Tips (Provided by Today)

UP NEXT

View original post here:
103-year-old shares secrets to longevity: Exercise and wine - msnNOW

The secret to long life expectancy is to follow a healthy lifestyle - regularly exercising, limiting alcohol intake, not smoking and eating a healthy balanced diet. When it comes to eating a healthy diet, the NHS recommends eating at least five portions of a variety of fruit and vegetables every day, basing meals on higher fibre starchy foods like potatoes, bread, rice or pasta, having some dairy or dairy alternatives, some protein, choosing unsaturated oils and spreads, and eating them in small amounts, and drinking plenty of fluids. A new study also suggests a different approach to meal times and how it could impact on your health.

In the study with the National Institute of Ageing (NIA) and the National Institutes of Health, longer daily fasting times and how it could improve health and longevity was analysed. The study noted: Increasing time between meals made male mice healthier overall and live longer compared to mice who at more frequently. Scientists from the University of Wisconsin-Madison and the Pennington Biomedical Research Centre, Baton Rouge, Louisiana , reports that health and longevity improved with increased fasting time, regardless of what the mice ate or how many calories they consumed. https://www.sciencedaily.com/releases/2018/09/180906123305.htm

DONT MISS

NIA director, Dr Richard J. Hodes said: This study showed that mice who ate one meal per day and thus had the longest fasting period, seemed to have a longer lifespan and better outcomes for common age-related liver disease and metabolic disorders.

"These intriguing results in an animal model show that the interplay of total caloric intake and the length of feeding and fasting periods deserves a closer look.

See original here:
How to live longer: Following this diet once a month could increase your life expectancy - Express

Visit the News Hub

Long life study explores genetics of extreme longevity

A new grant from the National Institute on Aging of the National Institutes of Health (NIH) supports research into the mysteries of extreme longevity. Researchers at Washington University School of Medicine in St. Louis are leading the Long Life Family Study, which includes several generations of families with unusual concentrations of long-lived individuals. The goal is to uncover genetic factors that play roles in long life spans.

Washington University School of Medicine in St. Louis has received a $68 million grant to investigate and discover what contributes to extreme longevity. The researchers are studying hundreds of families over several generations with individuals who have had exceptionally long lives. Many of these families have unusual concentrations of people living to at least age 100.

The goal of the Long Life Family Study, funded by the National Institute on Aging of the National Institutes of Health (NIH), is to identify genetic factors that contribute to exceptional longevity. Such information could lead to new therapeutics or other health innovations to help people live longer, healthier lives.

These families provide a unique opportunity for finding genetic links to long life spans, said principal investigator Michael A. Province, PhD, a Washington University professor of genetics. Remarkably, many study participants in the older generations are unusually healthy for their ages. We think we will find clues in their DNA that suggest how they might be protected from common diseases, such as diabetes or Alzheimers disease or, at the very least, uncover genetic factors that might delay the onset of these health problems.

The School of Medicine is the coordinating center for the project, which has field centers at Boston University, Columbia University, the University of Pittsburgh and the University of Southern Denmark. Province and Mary K. Wojczynski, PhD, an assistant professor of genetics at Washington University, lead the primary site and coordinate collaborations among the field sites and the University of Minnesota, where the laboratory for analyzing blood samples is located.

The study includes almost 5,000 individuals from three generations of 539 families across the United States and Denmark, first recruited from 2006 through 2009. The average age of representatives of the oldest generation in the study was 90 at that time, with some individuals exceeding 110. Those in the second generation of these families now average over 70 years of age, and the grandchildren of the oldest group are now in their 50s, on average. Studying multiple generations of families with histories of long lives presents the opportunity to study individuals who have a greater chance of reaching older ages. In particular, it provides the ability to study such individuals when they are younger and not yet obviously different from those with shorter life spans.

When we study long-lived people, we would really like to be able to travel back in time and study them before they reach older ages to see how they might differ from the general population when those differences might not yet be obvious, Province said. Our earlier findings from this study have shown that individuals in the second generation are healthier, on average, than individuals from families with more typical longevity, when measured, for example, in middle age. But these healthier traits vary by family. For example, some long-lived families might tend to have lower blood pressure while others might have better cognition into later life, and still others might have better lung function or grip strength. Across these families, there is no single factor that stands out as the main reason for the long health and life spans.

The researchers suspect this variability may be linked to specific rare genetic variants that may protect such families from the harmful effects of aging in a variety of ways. The new funding will support whole genome sequencing of study participants in an effort to identify special protective variations in the DNA.

The researchers also will study the consequences of such differences in DNA through analyzing what effects they might have on the proteins, metabolites and other molecules that have a direct impact on the bodys biology. Such measures change with age, and the researchers are interested in comparing these with more average populations over their life spans. The comparison group is composed of participants from the well-known Framingham Heart Study, which has been tracking the health of multiple generations of families living in Framingham, Mass., since that study began in 1948. The researchers said less than 1% of families participating in the Framingham Heart Study meet the longevity criteria of the Long Life Family Study.

One genetic characteristic that stands out in some but not all long-lived families is the length of telomeres, or the end caps on chromosomes that protect the DNA from damage. Every time a cell divides, the telomeres get a little shorter, and shorter telomeres have been associated with chronic diseases, such as diabetes, heart disease, dementia and other disorders common among elderly people. Long-lived families seem to have longer than average telomeres.

Telomere length might be one key component of healthy aging, Province said. There is evidence that healthy behaviors like exercise can protect telomere length or even extend it. But there is a genetic component to it as well. Some people just naturally have longer telomeres, or at least appear to have resilient telomeres. And that is the case in many of the families were studying. Based on that data, we have honed in on a gene that could be involved in telomere length, and this new grant will help us explore that possibility and other new avenues further.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

View post:
Families with long, healthy life spans focus of $68 million grant - Washington University School of Medicine in St. Louis

Washington (AFP)

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

- Cures -

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

- Bioterrorism -

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

2019 AFP

Read more:
2019: the year gene therapy came of age - RFI

NEW YORK, Dec. 2, 2019 /PRNewswire/ --

Nerve Repair and Regeneration market worldwide is projected to grow by US$7.3 Billion, driven by a compounded growth of 12.6%. Biomaterials, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.6%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.1 Billion by the year 2025, Biomaterials will bring in healthy gains adding significant momentum to global growth.

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

- Representing the developed world, the United States will maintain a 11.3% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$288.1 Million to the region's size and clout in the next 5 to 6 years. Over US$242.9 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Biomaterials will reach a market size of US$112 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16% over the next couple of years and add approximately US$1.7 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others, Abbott Laboratories; Baxter International, Inc.; Boston Scientific Corporation; Integra LifeSciences Holdings Corporation; LivaNova PLC; Medtronic PLC; NeuroPace, Inc.; Nevro Corp.; Nuvectra Corporation; Orthomed; Polyganics BV; Stryker Corporation

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Neuroregeneration - A Prelude Rise in Aging Population, and High Incidence of Neurological Disorders Drive the Global Nerve Repair and Regeneration Market Neurostimulation and Neuromodulation Devices- Largest Segment Biomaterials to Grow at a Faster Rate Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Nerve Connectors Technological Advancements and Product Innovations - A Key Growth Driver Innovation in Deep Brain Stimulation for Parkinson?s Disease Innovations in Spinal Cord Stimulation for Pain Global Competitor Market Shares Nerve Repair and Regeneration Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Biomaterials (Product) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Biomaterials (Product) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Biomaterials (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Neurostimulation and Modulation Devices (Product) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Neurostimulation and Modulation Devices (Product) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Neurostimulation and Modulation Devices (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurorrhaphy (Application) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2018-2025 Table 11: Neurorrhaphy (Application) Retrospective Demand Analysis in US$ Million by Region/Country: 2009-2017 Table 12: Neurorrhaphy (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Nerve Grafting (Application) Demand Potential Worldwide in US$ Million by Region/Country: 2018-2025 Table 14: Nerve Grafting (Application) Historic Sales Analysis in US$ Million by Region/Country: 2009-2017 Table 15: Nerve Grafting (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Stem Cell Therapy (Application) Worldwide Latent Demand Forecasts in US$ Million by Region/Country: 2018-2025 Table 17: Stem Cell Therapy (Application) Global Historic Analysis in US$ Million by Region/Country: 2009-2017 Table 18: Stem Cell Therapy (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Neurostimulation Surgery (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2018 through 2025 Table 20: Neurostimulation Surgery (Application) Analysis of Historic Sales in US$ Million by Region/Country for the Years 2009 to 2017 Table 21: Neurostimulation Surgery (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Nerve Repair and Regeneration Market Share (in %) by Company: 2019 & 2025 Table 22: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 23: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Million for 2009-2017 Table 24: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 25: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 26: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Million for 2009-2017 Table 27: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 CANADA Table 28: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 29: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 30: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 31: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 33: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 JAPAN Table 34: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 35: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 36: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 37: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 38: Japanese Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 39: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 CHINA Table 40: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 41: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Million by Product: 2009-2017 Table 42: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 43: Chinese Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 44: Nerve Repair and Regeneration Market Review in China in US$ Million by Application: 2009-2017 Table 45: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 EUROPE Market Facts & Figures European Nerve Repair and Regeneration Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Table 46: European Nerve Repair and Regeneration Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 47: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 48: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 49: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 50: Nerve Repair and Regeneration Market in Europe in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 51: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 52: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 53: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 54: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 FRANCE Table 55: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 56: French Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 57: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 58: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Million by Application: 2018-2025 Table 59: French Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 60: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 GERMANY Table 61: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 62: German Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 63: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 64: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 65: German Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 66: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 ITALY Table 67: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 68: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Million by Product: 2009-2017 Table 69: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 70: Italian Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 71: Nerve Repair and Regeneration Market Review in Italy in US$ Million by Application: 2009-2017 Table 72: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 73: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 74: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 75: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 76: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 77: United Kingdom Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 78: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 SPAIN Table 79: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 80: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 81: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 82: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 83: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 84: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 RUSSIA Table 85: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 86: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Million for 2009-2017 Table 87: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 89: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Million for 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 REST OF EUROPE Table 91: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 92: Nerve Repair and Regeneration Market in Rest of Europe in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 93: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 94: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 95: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 96: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 97: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 98: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 99: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 100: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 101: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 102: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 103: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Million by Application: 2018-2025 Table 104: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 105: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 AUSTRALIA Table 106: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 107: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 108: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 109: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 110: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 INDIA Table 112: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 113: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 114: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 117: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 SOUTH KOREA Table 118: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 119: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 120: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 121: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Application for the Period 2018-2025 Table 122: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Application: 2009-2017 Table 123: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 124: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 125: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 126: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 127: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 128: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 LATIN AMERICA Table 130: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Million: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 132: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 133: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 134: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Million by Product: 2009-2017 Table 135: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 136: Latin American Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 137: Nerve Repair and Regeneration Market Review in Latin America in US$ Million by Application: 2009-2017 Table 138: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 ARGENTINA Table 139: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Argentina in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 141: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 142: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 143: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 144: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 BRAZIL Table 145: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 146: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 147: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Million by Application: 2018-2025 Table 149: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 150: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 MEXICO Table 151: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 152: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 153: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 155: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 157: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 158: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Million for 2009-2017 Table 159: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 160: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 161: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Million for 2009-2017 Table 162: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 MIDDLE EAST Table 163: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 164: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 165: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 166: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 167: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Million: 2009-2017 Table 168: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 169: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 170: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 171: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 IRAN Table 172: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 173: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 174: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 175: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 176: Iranian Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 ISRAEL Table 178: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 179: Nerve Repair and Regeneration Market in Israel in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 180: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 181: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 182: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 183: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 184: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 185: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Million by Product: 2009-2017 Table 186: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 187: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 188: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Million by Application: 2009-2017 Table 189: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 190: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 191: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 192: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2019 VS 2025 Table 193: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Application for the Period 2018-2025 Table 194: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Application: 2009-2017 Table 195: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 196: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 197: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 198: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 199: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 200: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 201: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 AFRICA Table 202: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 203: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Million for 2009-2017 Table 204: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 205: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 206: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Million for 2009-2017 Table 207: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBOTT LABORATORIES BAXTER INTERNATIONAL BOSTON SCIENTIFIC CORPORATION INTEGRA LIFESCIENCES HOLDINGS CORPORATION LIVANOVA PLC MEDTRONIC PLC NEUROPACE NEVRO CORP. NUVECTRA CORPORATION ORTHOMED POLYGANICS BV STRYKER CORPORATION

V. CURATED RESEARCHRead the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

See the rest here:
Global Nerve Repair and Regeneration Industry - PRNewswire

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Autologous Stem Cell and Non-Stem Cell Based Therapies industry overview and then goes into each and every detail.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Autologous Stem Cell and Non-Stem Cell Based Therapies also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market competition by top manufacturers/players, with Autologous Stem Cell and Non-Stem Cell Based Therapies sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: NeoStem, Inc., Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/523

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/523

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics in the world mainly, the worldwide 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Autologous Stem Cell and Non-Stem Cell Based Therapies market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/523

In this study, the years considered to estimate the market size of 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

The rest is here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Growth and Demand Analysis By Global Top Key Players Like and Others 2018-2026 - The...

DUBLIN, Dec. 6, 2019 /PRNewswire/ -- The "The State of Personalized/ Precision Medicine" report has been added to ResearchAndMarkets.com's offering.

This report covers current and future challenges for the development and launch of these medicines, focusing on challenges with transitioning these therapies from bench to bedside and demonstrating efficacy in order to secure reimbursement.

Report ScopeDefinition of Personalized/Precision Medicine - Key attributes of personalized/precision medicine, examining and contrasting definitions by regulatory bodies and KOL respondents.

Personalized Medicine-Impact on Healthcare - Key factors to impacting healthcare for patients and stakeholders providing respondent mix by region and organization size.

Marketed Products - Detailed information is provided for key personalized/precision medicines, including case studies for marketed oncology and rare disease therapeutics.

Pipeline Products - The diverse Phase III pipeline is presented, including detailed information on key candidate's mechanism of action and clinical trial parameters.

Investment in Personalized Medicine - Investment in personalized medicine by indication and clinical trial design and approaches are presented, with case studies for three ongoing oncology trials being considered.

Market Opportunities and Challenges - Key areas of opportunity and roadblocks in developing, launching, and gaining reimbursement are analyzed by geography, company size, and seniority level.

Emerging Trends - Critical new trends, including the use of advanced digital technologies, are examined.Key Topics Covered

1. Preface

2. Executive Summary

3. Overview of Personalized/Precision Medicine3.1 Definition3.2 Definition of Personalized/Precision Medicine3.3 KOL and Payer Perspecive3.4 Key Attributes of Personalized Medicine Therapy3.5 Types of Biomarkers and Diagnostics

4. Impact of Personalized Medicine on Healthcare4.1 Personalized Medicine - Impact on Healthcare - Patients4.2 Advantages of Personalized Medicine - Patients4.3 Role of Personalized Medicine in Clinical Unmet Needs4.4 Personalized Medicine - Impact on Healthcare - Drug Developers' Perspective4.5 Advantages of Personalized Medicine to Drug Developers4.6 Personalized Medicine - Impact on Healthcare - Health System

5. Key Marketed Products

6. Pipeline Products

7. Investment in Personalized Medicine

8. Deal-Making Landscape

9. Market Opportunities and Challenges

10. Pricing, Reimbursement, and Regulatory Strategy

11. Personalized Medicine - Emerging Trends

12. Summary of Key Findings

13. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/v886fo

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-state-of-personalizedprecision-medicine-in-2019-impact-on-healthcare-marketed-products-pipeline-products-investments-market-opportunities--challenges-emerging-trends-300970564.html

SOURCE Research and Markets

Read the rest here:
The State of Personalized/Precision Medicine in 2019: Impact on Healthcare, Marketed Products, Pipeline Products, Investments, Market Opportunities &...

Ritu Jha-

Prasun Mishra, founding President and CEO of the American Association for Precision Medicine (AAPM) says the demise of his elder sister to pancreatic cancer led him to this work to create awareness about precision (or personalized) medicine.

It was a kind of a calling for me, Mishra told indica at the AAPM annual meeting 2019 held this past month at the Santa Clara Convention Center. Initially I was very sad for my personal loss but eventually I realized it was not just me. Everybody is facing the same thing and has the same story and I am just one of them.

The daylong meeting was based on the theme Accelerating Precision Medicine and Transforming Patient Health. It was attended by both national and international professors, experts, and thought leaders in the fields of precision medicine, life science, biotech, MedTech and pharma.

Mishra, a serial entrepreneur is the Founder and CEO of Agility Pharmaceuticals, founded by AAPM in 2017 with a mission to save lives by accelerating the field of precision medicine through research, education, communication, and collaboration.

Mishra says it was not easy to build a precision medicine community and there was no non-profit voice before them. There were for profit activists out there but the real community message is hard to create. It was also hard to have a meaningful dialogue about precision medicine to create resources and funds.

In our community we have medical doctors, pharma executives, investors, entrepreneurs, and scientists and are pulling our heads together to solve the toughest problem, he added.

A lot of work was done in the previous decade in the field of precision medicine at the universities, even pharma companies and precision medicine come under health care but it is still in the burgeoning stage.

When asked if lifestyle is a part of precision medicine, Mishra said, It includes lifestyle and yes, lifestyle plays a big role. We are monitoring the patients health and behavior [to see] how it impacts their life [] and trying to see how we could through technology and resources predict, based on lifestyle what outcome [the patient] would have.

When asked about President Barack Obamas launch of the Precision Medicine Initiative in 2015 and the $215 million investment in the Presidents 2016 Budget Mishra gave the example said even private companies like Verily, a Google company, they are working on it and have been profiling patients lifestyle, including sleep pattern and genomics data. They have recently acquired Fitbit for $2.1 billion.

So the question is what led to the awareness of precision medicine? Technology or the growing Cancer killer disease? Mishra believes its both. Its a combination and of course there is frustration for not able to make a difference in the life of loved ones and that is the main cause.

During his presentation, Mishra also highlighted another move by Google that might help boost this growing demand, said, I think Google Quantum computers will be very good [at performing] certain tasks in the future and Quantum computers is much needed as it works much faster than regular computers.

But there are challenges, when it comes to data, Mishra stated that the problem is there are a lot of manual facts in the healthcare system and its on paper in the medical records.

Now we are trying to work together as a community and as a consortium on how can we solve that issue. So that manual data needs to be digitized or you can say the whole health care system needs big a U-Haul, and there are many hurdles and we have to move forward and solve each one at a time.

There are many hurdles still. We have a lot of unstructured data and we need defined data sets. We have to make an innovation to collect that data, Mishra said.

When asked if there is awareness of personalized medicine among the South Asian community, he said that precision medicines goal is to define the community, whether its the Indian or American community.

Based on how you respond to disease we are prone to certain things and diet and our lifestyle, and it would be good to have a community to have genomics data, some companies are working on but still we be are far behind in terms of collecting massive data. In India certain organizations are working. We could come together as a community.

Adding further he said as a community [coming] together would generate a pool of data and would help [figure out] what kind of medicine would respond to them.

Precision medicine is also about growing people, individual groups of ethnicity, community and similar genetic group and then treating and doing research. What are the common genetic factors that are missing and gained and use that knowledge to deliver the promise of precision medicine, said Mishra and added that the next 10 years, are going to be very exciting.

I have predicted that in 5 years and as technology is moving forward exponentially we could do so many things and with AI intervention, we could even detect diabetic retinopathy, Radiology, Mishra said and that would even help rural areas where there are no physicians.

The future is very bright and as a community, if we are passionate about making a difference, we will make the progress that is needed in 10 years or earlier.

Another speaker at the conference Pritmohinder Gill, PhD, Associate Professor at the Arkansas Childrens Research Institute, UAMS said the demand grew because of the growing cancer.

Cancer is the area where more therapeutic value from precision medicine has gone. It is the main beneficiary because we are able to target those particular genes in a particular individual, said Professor Gill.

But he sees a long way to go as its expansive and needs more research and both medicine and technology are very expensive.

He said a single medicine could cost $3000 per sample. Some companies commercialize and can do that for 1500 dollars and many places of academia has fewer resources and infrastructure to support new AI-based technology.

UAMS has no money, and without the growth of technology and AI and if you dont have support its very hard to say which gene is impacting you and your condition. Certainly many of the psychiatric disorders are multi-gene.

Without research, there is no understanding of what is happening. The key is research and only after research, you can take these findings to that side.

Pointing to the recent drugs approved by the FDA he said that in 2018, 42 percent of drugs approved by the FDA were personalized medicine drugs.

When asked how to reduce the cost, Professor Gill said that in Norway they have a population of 6 million and all the inhabitants in Norway have their whole genome sequencing done.

The UK is planning now and its in their database and physicians can access it for writing a prescription.

Thats basically where healthcare will move.

But Prof. Gill believes it would take 50 years because its all money and needs regulation and it depends on how the FDA is doing.

Meanwhile, Dr. Sanjeev Jain, CEO of The Columbia Asthma & Allergy Clinic who spoke at the panel, Role of Physicians Transforming Precision Health says precision is useful in helping to customize the treatment plan for each individual when doing allergy immune therapy.

He said he had lots of data but not enough resources, so he is looking forward to collaborating with Stanford University to build a joint database.

Currently the database is going to be focused on food allergies. Hopefully in future we can do it for other diseases, said Dr. Jain.

View post:
Is Precision Medicine the Future of Healthcare? - indica News

December 06, 2019 -In recent years, genomics and genetic data have emerged as an innovative area of research that could potentially transform healthcare. This information could accelerate precision medicine, paving the way for individualized therapies tailored to each person.

Studies have examined how genomics could improve care for Alzheimers, heart failure, and a number of other diseases, leading to a more personalized standard of treatment.

However, this new source of information could also come with unprecedented challenges. Organizations will need new ways of storing this data, and providers and patients will need to be prepared to handle the answers genomic information could hold.

What are some of the benefits of using genomics in healthcare, and how can the industry overcome the possible challenges that can accompany this information?

Proactive, not reactive, care delivery

READ MORE: Big Data Analytics, Precision Medicine Top Priorities in 2020

Using genomic data, providers can identify patients who are at high risk of developing certain conditions and better plan for treatments. This approach could be particularly helpful in proactively treating cognitive or behavioral disorders before people show signs of disease.

Recently, researchers from The Hospital for Sick Children (SickKids) and the University of Alberta found that testing the DNA of siblings of individuals with autism spectrum disorder (ASD) may be predictive of a future diagnosis even if symptoms arent yet apparent.

Genetic factors are the most likely reason we see a clustering of ASD related traits in families, said Dr. Stephen Scherer, Senior Scientist and Director of The Centre for Applied Genomics (TCAG) at SickKids, Director of the McLaughlin Centre at the University of Toronto and principal investigator of the study.

We wanted to investigate the possible benefits of genetic testing for infants whose older sibling had already been diagnosed with ASD. If we can identify those children early, we may be able to enroll them earlier in therapies.

In a separate study published in the American Journal of Psychiatry, a team from the University of North Carolina (UNC) at Chapel Hill used polygenic risk scores (PRS) based on genome-wide association studies to improve psychosis risk prediction in patients meeting high-risk criteria.

READ MORE: How Real-World Data Could Advance Clinical Trials, Precision Medicine

Previous studies reported the PRS discriminates persons with established schizophrenia from unaffected persons. Our study is the first to indicate the PRS predicts future psychosis suggesting a PRS may facilitate the development and eventual targeting of preemptive interventions, said Diana O. Perkins, MD, MPH, a professor of psychiatry in the UNC School of Medicine.

Individualized care that goes beyond the individual

One of the most exciting benefits of genomics and precision medicine is the promise of therapies that are tailored to meet each patients specific needs. Providers can access an individuals genetic code and better determine what sort of treatment is right for him or her, leading to better outcomes and lower costs.

However, genomics also has the potential to improve treatment beyond the level of the individual, boosting health and well-being for entire patient populations.

If the population health community and the precision medicine community would talk to each other more, I suspect they would find that they have a great deal in common, Jonathan Sheldon, former Global Vice President of Healthcare at Oracle Health Sciences, said in a 2017 interview with HealthITAnalytics.com.

READ MORE: How Precision Medicine Could Boost Chronic Disease Management

Precision medicine gives us the molecular tools to phenotype diseases, which you can then predict and manage at the population level.Genomics gives you that level of precision that is often lacking in risk stratification algorithms.They really enhance one another.Theyre not competitive in any way.

Healthcare organizations have recognized the complementary nature of genomics and population health management. In March 2018, the Healthy Nevada Project, a population health study combining genomic data with socioeconomic, environmental, and clinical information, entered its second collection phase.

The project aims to gather insights about how lifestyle interacts with genetics, improving population health for people in Nevada and around the world.

Genomics could also help researchers and providers uncover why particular conditions impact certain races or ethnicities more than others. A recent study published in the journal Nature showed that a genetic mutation linked to blood sugar levels occurs in one percent of Hispanic/Latino people and about six percent of African Americans, but very rare in people of European descent.

Our study confirmed that the apparent effects of the same genetic variant often vary across populations,saidSteve Buyske, a senior author and an associate professor in theDepartment of Statisticsat RutgersNew Brunswick. A genetic variant with a big effect in people of European descent may have a smaller effect in other populations, and vice versa.

These findings could help advance precision medicine treatments for entire populations, many of which may be underrepresented in studies and clinical trials.

More data, more problems

Although genomics and genetic data could give providers a more comprehensive picture of patient health, the industry still has significant data challenges to overcome before this information can be used at the point of care.

A March 2018 survey from Oracle and GenomeWeb showed that data management and storage were ranked among the top obstacles organizations currently face when trying to achieve their precision medicine goals.

Additionally, many survey participants who said they had no plans to pursue a precision medicine initiative cited insufficient technical infrastructure as their most significant barrier. Health systems will need to implement innovative data storage and management tools to realize the benefits of precision medicine and genomics.

The science is changing rapidly every day. Today, there are literally thousands of variants of unknown significance in every patient, and tomorrow some of those variants will be associated with a syndrome, Joel Diamond, MD, adjunct associate professor of biomedical informatics at the University of Pittsburgh, told HealthITAnalytics.com.

The industry needs an enterprise technology solution that can keep up with new advancements, as well as recognize when changes occur in a patient's clinical condition.

Diamond said that organizations should adopt system-wide standards and strategies that make genomics part of a comprehensive solution, as well as adopt advanced technologies like FHIR.

Even without genetic data standards, organizations should have a genetic data strategy in place, said Diamond.Instead of storing this data in PDFs, genetic information can be stored in various files that the organization has right now, in a standard way that allows the data to be usable down the line.

Patient, provider education

As advanced genetic testing becomes more affordable and accessible, more people will be looking to better understand their health risks. While this could help accelerate precision medicine, providers will need to be sure theyre ready to discuss the results of these tests with their patients.

In 2017, Wamberg Genomic Advisors showed that 16 percent of patients are confused by their genetic testing results, and an additional six percent experienced mild depression or anxiety after reviewing their personal data.

Providers, on their part, may not feel totally prepared to talk with their patients about these results. A recent survey of 130 primary care physicians showed that just 23 percent said they would feel comfortable discussing genetics as a risk factor for common diseases.

Geisinger Health System has recently integrated genomics with routine clinical care, and the organization has made patient and provider education a top priority.

One of the challenges we've tried to address up front is the education aspect what the results mean, both on the patient side and the clinician side, she said.

We've developed what we call Just in Time documents that doctors can give to their patients, which say, This is the information that we learned about you. This is what you need to do now given this information. This is what you need to monitor over time, and this is what you need to do long term. Anticipating the needs of patients and providers as they get this new type of information is important.

While there are challenges to leveraging genomics and genetics in healthcare, the potential benefits the information could provide outweigh the barriers. With innovative data storage tools and strategies to educate patients and providers about this new data, health systems could accelerate precision medicine and personalized treatments.

Continue reading here:
Evaluating the Benefits and Challenges of Genomics in Healthcare - HealthITAnalytics.com